15 Results for "

murine sepsis

" in MedChemExpress (MCE) Product Catalog:
Products (15)

15 Results for "murine sepsis" in MCE Product Catalog:

  • Targets Recommended:
  • Disease Areas Recommended:
26
26 Publications Verification
Cat. No.: HY-100574A
CAS No.: 1373232-26-8
Purity:  99.82%
Cl-amidine hydrochloride is an orally active peptidylarginine deminase (PAD) inhibitor, with IC50 values of 0.8 μM, 6.2 μM and 5.9 μM for PAD1, PAD3, and PAD4, respectively. Cl-amidine hydrochloride induces apoptosis in cancer cells. Cl-amidine hydrochloride induces microRNA (miR)-16 (miRNA-16, microRNA-16) expression and causes cell cycle arrest. Cl-Amidine hydrochloride prevents histone 3 citrullination and neutrophil extracellular trap formation, and improves survival in a murine sepsis model .
loading...
    loading...
26
26 Publications Verification
Cat. No.: HY-100574B
CAS No.: 1043444-18-3
Cl-amidine TFA is an orally active peptidylarginine deminase (PAD) inhibitor, with IC50 values of 0.8 μM, 6.2 μM and 5.9 μM for PAD1, PAD3, and PAD4, respectively. Cl-amidine TFA induces apoptosis in cancer cells. Cl-amidine TFA induces microRNA (miR)-16 (miRNA-16, microRNA-16) expression and causes cell cycle arrest. Cl-Amidine TFA prevents histone 3 citrullination and neutrophil extracellular trap formation, and improves survival in a murine sepsis model .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99008
CAS No.: 2417175-94-9
Synonyms: IC14
Atibuclimab (IC14), is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab attenuates Lipopolysaccharides (HY-D1056) (LPS)-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist. Atibuclimab can be used for the research of amyotrophic lateral sclerosis, sepsis, community-acquired pneumonia, or acute lung injury .
loading...
    loading...
Cat. No.: HY-100574
CAS No.: 913723-61-2
Cl-amidine is an orally active peptidylarginine deminase (PAD) inhibitor, with IC50 values of 0.8 μM, 6.2 μM and 5.9 μM for PAD1, PAD3, and PAD4, respectively. Cl-amidine induces apoptosis in cancer cells. Cl-amidine induces microRNA (miR)-16 (miRNA-16, microRNA-16) expression and causes cell cycle arrest. Cl-Amidine prevents histone 3 citrullination and neutrophil extracellular trap formation, and improves survival in a murine sepsis model .
loading...
    loading...
Cat. No.: HY-146066
CAS No.: 2108714-20-9
Purity:  99.54%
α7 nAchR-JAK2-STAT3 agonist 1 is a potent α7 nAchR-JAK2-STAT3 agonist, with an IC50 value of 0.32 μM for nitric oxide (NO). α7 nAchR-JAK2-STAT3 agonist 1 effectively suppresses the expression of iNOS, IL-1β, and IL-6 in murine RAW264.7 macrophages. α7 nAchR-JAK2-STAT3 agonist 1 can inhibit LPS-induced NO release, NF-κB activation and cytokine production. α7 nAchR-JAK2-STAT3 can be used for researching sepsis .
loading...
    loading...
Cat. No.: HY-P10950A
Target:  

PD-1/PD-L1 Apoptosis

Research Areas:  

Inflammation/Immunology Cancer

PD-L1 inhibitory peptide TFA is an inhibitor targeting the PD-1/PD-L1 interaction. PD-L1 inhibitory peptide TFA inhibits the PD-1-mediated apoptosis signaling pathway, maintains the survival and activity of T cells, activates the anti-tumor effect of cytotoxic T lymphocytes, and significantly improves the survival rate of mice in fungal sepsis models. PD-L1 inhibitory peptide TFA can be used for research on sepsis, breast cancer and other related diseases, as well as immunotherapy .
loading...
    loading...
Cat. No.: HY-146066A
Purity:  98.45%
Target:  

nAChR JAK STAT NO Synthase

Research Areas:  

Others

(R)-α7 nAchR-JAK2-STAT3 agonist 1 is the R-enantiomer of α7 nAchR-JAK2-STAT3 agonist 1 (HY-146066). α7 nAchR-JAK2-STAT3 agonist 1 is a potent α7 nAchR-JAK2-STAT3 agonist, with an IC50 value of 0.32 μM for nitric oxide (NO). α7 nAchR-JAK2-STAT3 agonist 1 effectively suppresses the expression of iNOS, IL-1β, and IL-6 in murine RAW264.7 macrophages. α7 nAchR-JAK2-STAT3 agonist 1 can inhibit LPS-induced NO release, NF-κB activation and cytokine production. α7 nAchR-JAK2-STAT3 can be used for researching sepsis .
loading...
    loading...
Cat. No.: HY-178949
Research Areas:  

Infection

MRSA antibiotic 3 (Compound C8) is a small-molecule antibiotic active against Methicillin (HY-121544)-resistant Staphylococcus aureus (MRSA), showing a MIC of 0.5 μg/mL against the standard S. aureus strain (ATCC 29213). MRSA antibiotic 3 potently inhibits the ATPase activity of S. aureus DNA gyrase with an IC50 of 0.32 μM. MRSA antibiotic 3 exhibits strong inhibitory activity against five clinical MRSA isolates, with MIC values ranging from 0.5 to 1 μg/mL. MRSA antibiotic 3 demonstrates negligible cytotoxicity at effective antibacterial concentrations and causes no hemolysis in erythrocytes even at extremely high concentrations. MRSA antibiotic 3 shows significant protective effects in both Galleria mellonella infection and murine sepsis models .
loading...
    loading...
Cat. No.: HY-P5949
CAS No.: 2569135-98-2
Target:  

Bacterial

Research Areas:  

Infection

AMPR-22 is an antimicrobial peptide. AMPR-22 can bind to the bacterial membrane and induces membrane permeabilization. AMPR-22 is effective against murine model of sepsis induced by MDR strains
loading...
    loading...
Cat. No.: HY-P11879
CAS No.: 2567713-50-0
Target:  

SARS-CoV

LSALT peptide is a selective DPEP-1 inhibitor with selectivity over DPEP2/3. LSALT peptide inhibits neutrophil and monocyte/macrophage recruitment, inflammation, and tissue injury. LSALT peptide reduces kidney damage, improves survival in murine sepsis and endotoxemia models. LSALT peptide can be used for the research of COVID-19, sepsis, acute respiratory distress syndrome, and acute kidney injury .
loading...
    loading...
Cat. No.: HY-183296
NLRP3-IN-91 is a potent NLRP3 inflammasome inhibitor with a Kd of 558.4 nM. NLRP3-IN-91 directly targets the NLRP3 NACHT domain, blocks inflammasome assembly and activation, and exerts anti-inflammatory effects. NLRP3-IN-91 increases survival time in a murine model of LPS (HY-D1056)-induced sepsis. NLRP3-IN-91 can be used for the research of sepsis .
loading...
    loading...
Cat. No.: HY-182417
CAS No.: 351372-19-5
Target:  

Bacterial Topoisomerase

Research Areas:  

Infection

PD 0305970 is an orally active bacterial gyrase and topoisomerase inhibitor. PD 0305970 shows exceptional activity against gram-positive and fastidious organisms and more modest activity against gram-negative species. PD 0305970 shows low spontaneous resistance frequencies. PD 0305970 shows antibacterial efficacy in murine streptococcal sepsis and pneumococcal pneumonia models. PD 0305970 can be used for the research of bacterial infection .
loading...
    loading...
Cat. No.: HY-184691
CAS No.: 3109806-14-3
HSC-4 is an orally active anti-inflammatory agent and a derivative of Hederacoside C (HY-N0253). HSC-4 inhibits the secretion of IL-6. HSC-4 exerts protective effects in mouse models of systemic sepsis and acute lung injury. HSC-4 can be used for the research of acute lung injury and systemic sepsis .
loading...
    loading...
Cat. No.: HY-181671
Target:  

Bacterial

Research Areas:  

Infection

Antibacterial agent 324 is an amphipathic antibacterial agent. Antibacterial agent 324 exhibits selective activity against Gram-positive bacteria, with limited activity against enterococci and weak activity against Gram-negative bacteria .
loading...
    loading...
Cat. No.: HY-P11791
CAS No.: 1644397-65-8
Target:  

Endogenous Metabolite

Research Areas:  

Infection

nNIF peptide is an endogenous polypeptide detectable in human umbilical cords and neonatal blood. nNIF peptide specifically inhibits neutrophil extracellular trap (NETs) formation by neutrophils without interfering with other key immune functions of neutrophils. nNIF peptide can be used in studies related to COVID-19 acute respiratory distress syndrome, polymicrobial sepsis, and neonatal infectious peritonitis .
loading...
    loading...
  • 1